Back to Research Home
GSKGlaxoSmithKline PLC ADR
Health Care · Biotechnology: Pharmaceutical Preparations · Large
$50.75−0.90%
As of 23 Oct 2026Mkt cap $101B
Stage 13
WAIT
Fundamentals
41.8/75
Technical
7.7/15
Independent
49.5/90
GCAE viewevidence is stale or freshness is unknown
Price
- 1M
- +2.2%
- 3M
- −2.4%
- 6M
- −6.8%
- 1Y
- +14.7%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 23.3%
- Operating margin
- 22.2%
- FCF margin
- 19.6%
- Current ratio
- 0.8x
Growth
- Revenue growth
- +7.4%Latest FY YoY
- Revenue CAGR
- +6.1%
- EPS CAGR
- +5.3%
- FCF CAGR
- −3.3%
Capital
- Share-count trend
- +0.1%3Y annualised
- Net debt
- $20.4B2.0x OCF
Annual trend
- CAGR 2021–2025
- +6.1%
- Latest · 2025
- $43B
- YoY
- +7.4%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
evidence is stale or freshness is unknown
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-28
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- stale
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded